Mate - show us on a chart Many are asking because (like me) we...

First 921 Last

Share
Profile

Follow
Wise_One

17,357 Posts.

1340

26/06/24

18:21

Post #: 74498645
Share

Originally posted by lockitt: ↑

Two tops below a top on the chart today and below the short term MA.
Looks like the MA is becoming resistance after all.

Who would have thunk when we now have "full enrollment", was that not the holy grail? As if that was ever going to make any difference. Even though you were all on about full enrollment for ages.
What difference was that ever going to make REALLY?
I will tell you - SFA.
Full enrollment proves nothing except we have enough poor unfortunate boys to start testing.
ONLY POSITIVE RESULTS MATTER.

I will give you a few pointers as to what will get the sp really rolling.
1. The successful completion of the trials or at least a general consensus that the trials are going well and likely to be successful.
2. A strong partnership agreement.

Nothing else is going to make the market happy with this company and it's litany of disappointments.

I remain a true believer in PER but insulting me without even taking the effort to learn what I am talking about ( gaps in the sp ). Google the damn thing and learn , Don't expect it to be done for you.
I have been in PER for close to five years and have seen only heartache, all while reading the positive crap posted on HC.

You say that if I want people to believe me then I should put up graphs, but believe me, I don't give a blurt if you believe me or not.

There are some people who read what I say who appreciate my points.

Lockitt

Expand

Mate - show us on a chart

Many are asking because (like me) we don’t see it

It’s not that hard to show (if it exists)

PER Price at posting: 8.2¢ Sentiment: Buy Disclosure: Held
7 Upvote

1 Great analysis

Reply

Top Stories

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

There are more pages in this discussion • 100 more messages in this thread...

First 921 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.1¢		Change -0.002(2.41%)		Mkt cap ! $73.02M

Open	High	Low	Value	Volume
8.1¢	8.2¢	8.0¢	$39.27K	485.4K

Buyers (Bids)

No.	Vol.	Price($)
1	365000	8.2¢

Sellers (Offers)

Price($)	Vol.	No.
8.4¢	57142	1

View Market Depth

No.	Vol.	Price($)
1	365000	0.082
2	37265	0.081
3	88252	0.080
2	212658	0.078
1	108571	0.077

Price($)	Vol.	No.
0.084	57142	1
0.085	90800	2
0.086	106100	2
0.087	158719	2
0.088	166793	7

Last trade - 14.51pm 11/07/2024 (20 minute delay)

PER (ASX) Chart

Mate - show us on a chart Many are asking because (like me) we...

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Canadian fieldwork yields multiple pegmatites for Trinex

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Mate - show us on a chart Many are asking because (like me) we...

Top Stories

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Canadian fieldwork yields multiple pegmatites for Trinex

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News